{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T12:32:47Z","timestamp":1754483567374},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,2]]},"DOI":"10.7759\/cureus.61526","type":"journal-article","created":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T15:27:31Z","timestamp":1717342051000},"source":"Crossref","is-referenced-by-count":2,"title":["A Comparison of Rosuvastatin Monotherapy and Rosuvastatin Plus Ezetimibe Combination Therapy in Patients With Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.7759","author":[{"given":"Samuel K","family":"Dadzie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Godfrey","family":"Tabowei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mandeep","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saeed","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aayushi","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaldoun","family":"Khreis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adil","family":"Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01655-5","article-title":"Type 2 diabetes","volume":"400","author":"Ahmad E","year":"2022","unstructured":"Ahmad E, Lim S, Lamptey R, Webb DR, Davies MJ. Type 2 diabetes. Lancet. 2022, 400:1803-20. 10.1016\/S0140-6736(22)01655-5","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/ncpendmet1066","article-title":"Dyslipidemia in type 2 diabetes mellitus","volume":"5","author":"Mooradian AD","year":"2009","unstructured":"Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2009, 5:150-9. 10.1038\/ncpendmet1066","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(85)90224-8","article-title":"Lipids, diabetes, and coronary heart disease: insights from the Framingham Study","volume":"110","author":"Kannel WB","year":"1985","unstructured":"Kannel WB. Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J. 1985, 110:1100-7. 10.1016\/0002-8703(85)90224-8","journal-title":"Am Heart J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.20.11.1683","article-title":"U.K. Prospective Diabetes Study 27. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex","volume":"20","author":"U.K. Prospective Diabetes Study Group","year":"1997","unstructured":"U.K. Prospective Diabetes Study Group. U.K. Prospective Diabetes Study 27. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex. Diabetes Care. 1997, 20:1683-7. 10.2337\/diacare.20.11.1683","journal-title":"Diabetes Care"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone NJ","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, et al.. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation. 2014, 129:S1-45. 10.1161\/01.cir.0000437738.63853.7a","journal-title":"Circulation"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(03)00530-7","article-title":"Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial)","volume":"92","author":"Jones PH","year":"2003","unstructured":"Jones PH, Davidson MH, Stein EA, et al.. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003, 92:152-60. 10.1016\/S0002-9149(03)00530-7","journal-title":"Am J Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S1567-5688(03)00004-7","article-title":"Comparative pharmacology of rosuvastatin","volume":"4","author":"McTaggart F","year":"2003","unstructured":"McTaggart F. Comparative pharmacology of rosuvastatin. Atheroscler Suppl. 2003, 4:9-14. 10.1016\/S1567-5688(03)00004-7","journal-title":"Atheroscler Suppl"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000034044.95911.dc","article-title":"Inhibition of intestinal cholesterol absorption by ezetimibe in humans","volume":"106","author":"Sudhop T","year":"2002","unstructured":"Sudhop T, L\u00fctjohann D, Kodal A, et al.. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 2002, 106:1943-8. 10.1161\/01.cir.0000034044.95911.dc","journal-title":"Circulation"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)80281-3","article-title":"Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor","volume":"25","author":"Jeu L","year":"2003","unstructured":"Jeu L, Cheng JW. Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor. Clin Ther. 2003, 25:2352-87. 10.1016\/S0149-2918(03)80281-3","journal-title":"Clin Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S332352","article-title":"Combination therapy of ezetimibe and rosuvastatin for dyslipidemia: current insights","volume":"16","author":"Chilbert MR","year":"2022","unstructured":"Chilbert MR, VanDuyn D, Salah S, Clark CM, Ma Q. Combination therapy of ezetimibe and rosuvastatin for dyslipidemia: current insights. Drug Des Devel Ther. 2022, 16:2177-86. 10.2147\/DDDT.S332352","journal-title":"Drug Des Devel Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon CP","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, et al.. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015, 372:2387-97. 10.1056\/NEJMoa1410489","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2022.0402","article-title":"Comparative efficacy of rosuvastatin monotherapy and rosuvastatin\/ezetimibe combination therapy on insulin sensitivity and vascular inflammatory response in patients with type 2 diabetes mellitus","volume":"48","author":"Han JH","year":"2024","unstructured":"Han JH, Joung KH, Lee JC, et al.. Comparative efficacy of rosuvastatin monotherapy and rosuvastatin\/ezetimibe combination therapy on insulin sensitivity and vascular inflammatory response in patients with type 2 diabetes mellitus. Diabetes Metab J. 2024, 48:112-21. 10.4093\/dmj.2022.0402","journal-title":"Diabetes Metab J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2018.0124","article-title":"Comparison of the efficacy of rosuvastatin monotherapy 20 mg with rosuvastatin 5 mg and ezetimibe 10 mg combination therapy on lipid parameters in patients with type 2 diabetes mellitus","volume":"43","author":"Hwang YC","year":"2019","unstructured":"Hwang YC, Jun JE, Jeong IK, Ahn KJ, Chung HY. Comparison of the efficacy of rosuvastatin monotherapy 20 mg with rosuvastatin 5 mg and ezetimibe 10 mg combination therapy on lipid parameters in patients with type 2 diabetes mellitus. Diabetes Metab J. 2019, 43:582-9. 10.4093\/dmj.2018.0124","journal-title":"Diabetes Metab J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1336357","article-title":"Distinct effects of rosuvastatin and rosuvastatin\/ezetimibe on senescence markers of CD8+ T cells in patients with type 2 diabetes mellitus: a randomized controlled trial","volume":"15","author":"Ju SH","year":"2024","unstructured":"Ju SH, Lim JY, Song M, et al.. Distinct effects of rosuvastatin and rosuvastatin\/ezetimibe on senescence markers of CD8+ T cells in patients with type 2 diabetes mellitus: a randomized controlled trial. Front Endocrinol. 2024, 15:1336357. 10.3389\/fendo.2024.1336357","journal-title":"Front Endocrinol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-020-00778-1","article-title":"Comparison of the efficacy and safety of rosuvastatin\/ezetimibe combination therapy and rosuvastatin monotherapy on lipoprotein in patients with type 2 diabetes: multicenter randomized controlled study","volume":"11","author":"Lee J","year":"2020","unstructured":"Lee J, Hwang YC, Lee WJ, et al.. Comparison of the efficacy and safety of rosuvastatin\/ezetimibe combination therapy and rosuvastatin monotherapy on lipoprotein in patients with type 2 diabetes: multicenter randomized controlled study. Diabetes Ther. 2020, 11:859-71. 10.1007\/s13300-020-00778-1","journal-title":"Diabetes Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/1476-511X-12-137","article-title":"Efficacy of combination of ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes","volume":"12","author":"Torimoto K","year":"2013","unstructured":"Torimoto K, Okada Y, Mori H, et al.. Efficacy of combination of ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes. Lipids Health Dis. 2013, 12:137. 10.1186\/1476-511X-12-137","journal-title":"Lipids Health Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5922.2010.00181.x","article-title":"Lipid-altering efficacy of ezetimibe\/simvastatin 10\/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy","volume":"30","author":"Vaverkova H","year":"2012","unstructured":"Vaverkova H, Farnier M, Averna M, et al.. Lipid-altering efficacy of ezetimibe\/simvastatin 10\/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy. Cardiovasc Ther. 2012, 30:61-74. 10.1111\/j.1755-5922.2010.00181.x","journal-title":"Cardiovasc Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-019-1182-5","article-title":"Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature","volume":"19","author":"Yu M","year":"2020","unstructured":"Yu M, Liang C, Kong Q, Wang Y, Li M. Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature. Lipids Health Dis. 2020, 19:1. 10.1186\/s12944-019-1182-5","journal-title":"Lipids Health Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2165\/0129784-200808060-00004","article-title":"Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism","volume":"8","author":"Golomb BA","year":"2008","unstructured":"Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008, 8:373-418. 10.2165\/0129784-200808060-00004","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.113.001326","article-title":"Cholesterol levels and risk of hemorrhagic stroke: a systematic review and meta-analysis","volume":"44","author":"Wang X","year":"2013","unstructured":"Wang X, Dong Y, Qi X, Huang C, Hou L. Cholesterol levels and risk of hemorrhagic stroke: a systematic review and meta-analysis. Stroke. 2013, 44:1833-9. 10.1161\/STROKEAHA.113.001326","journal-title":"Stroke"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1988.03410130125037","article-title":"Low-density lipoprotein subclass patterns and risk of myocardial infarction","volume":"260","author":"Austin MA","year":"1988","unstructured":"Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988, 260:1917-21. 10.1001\/jama.1988.03410130125037","journal-title":"JAMA"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1161\/01.atv.12.12.1496","article-title":"LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes","volume":"12","author":"Feingold KR","year":"1992","unstructured":"Feingold KR, Grunfeld C, Pang M, Doerrler W, Krauss RM. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler Thromb. 1992, 12:1496-502. 10.1161\/01.atv.12.12.1496","journal-title":"Arterioscler Thromb"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2011.10.043","article-title":"Ezetimibe alone and in combination lowers the concentration of small, dense low-density lipoproteins in type 2 diabetes mellitus","volume":"220","author":"Winkler K","year":"2012","unstructured":"Winkler K, Jacob S, M\u00fcller-Schewe T, Hoffmann MM, Konrad T. Ezetimibe alone and in combination lowers the concentration of small, dense low-density lipoproteins in type 2 diabetes mellitus. Atherosclerosis. 2012, 220:189-93. 10.1016\/j.atherosclerosis.2011.10.043","journal-title":"Atherosclerosis"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2009.02163.x","article-title":"Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia","volume":"39","author":"Masuda D","year":"2009","unstructured":"Masuda D, Nakagawa-Toyama Y, Nakatani K, et al.. Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia. Eur J Clin Invest. 2009, 39:689-98. 10.1111\/j.1365-2362.2009.02163.x","journal-title":"Eur J Clin Invest"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.5551\/jat.4929","article-title":"Molecular mechanisms of ezetimibe-induced attenuation of postprandial hypertriglyceridemia","volume":"17","author":"Sandoval JC","year":"2010","unstructured":"Sandoval JC, Nakagawa-Toyama Y, Masuda D, et al.. Molecular mechanisms of ezetimibe-induced attenuation of postprandial hypertriglyceridemia. J Atheroscler Thromb. 2010, 17:914-24. 10.5551\/jat.4929","journal-title":"J Atheroscler Thromb"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175672","article-title":"Effects of statin therapy on glycemic control and insulin resistance: a systematic review and meta-analysis","volume":"947","author":"Alvarez-Jimenez L","year":"2023","unstructured":"Alvarez-Jimenez L, Morales-Palomo F, Moreno-Caba\u00f1as A, Ortega JF, Mora-Rodr\u00edguez R. Effects of statin therapy on glycemic control and insulin resistance: a systematic review and meta-analysis. Eur J Pharmacol. 2023, 947:175672. 10.1016\/j.ejphar.2023.175672","journal-title":"Eur J Pharmacol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_1677_21","article-title":"Reduction in HbA1c through lifestyle modification in newly diagnosed type 2 diabetes mellitus patient: a great feat","volume":"11","author":"Dixit JV","year":"2022","unstructured":"Dixit JV, Badgujar SY, Giri PA. Reduction in HbA1c through lifestyle modification in newly diagnosed type 2 diabetes mellitus patient: a great feat. J Family Med Prim Care. 2022, 11:3312-7. 10.4103\/jfmpc.jfmpc_1677_21","journal-title":"J Family Med Prim Care"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1186\/1758-5996-2-34","article-title":"Synergistic effect of simvastatin and ezetimibe on lipid and pro-inflammatory profiles in pre-diabetic subjects","volume":"2","author":"Kater AL","year":"2010","unstructured":"Kater AL, Batista MC, Ferreira SR. Synergistic effect of simvastatin and ezetimibe on lipid and pro-inflammatory profiles in pre-diabetic subjects. Diabetol Metab Syndr. 2010, 2:34. 10.1186\/1758-5996-2-34","journal-title":"Diabetol Metab Syndr"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/259454-a-comparison-of-rosuvastatin-monotherapy-and-rosuvastatin-plus-ezetimibe-combination-therapy-in-patients-with-type-2-diabetes-a-meta-analysis-of-randomized-controlled-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T15:27:36Z","timestamp":1717342056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/259454-a-comparison-of-rosuvastatin-monotherapy-and-rosuvastatin-plus-ezetimibe-combination-therapy-in-patients-with-type-2-diabetes-a-meta-analysis-of-randomized-controlled-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,2]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.61526","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,2]]}}}